Menu Search
Equities

Aurora Spine Corp

ASG:CVE

Aurora Spine Corp

Actions
Health CareMedical Equipment and Services
  • Price (CAD)0.455
  • Today's Change0.02 / 4.60%
  • Shares traded4.50k
  • 1 Year change-1.09%
  • Beta0.6775
Data delayed at least 15 minutes, as of Nov 14 2024 19:57 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Aurora Spine Corp's net income fell 11.93% from a loss of 1.50m to a larger loss of 1.68m despite relatively flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 47.89% to 51.95%.
Gross margin60.39%
Net profit margin-3.76%
Operating margin-3.76%
Return on assets-5.56%
Return on equity-14.52%
Return on investment-8.18%
More ▼

Cash flow in USDView more

In 2023, Aurora Spine Corp increased its cash reserves by 81.11%, or 343.43k. Cash Flow from Financing totalled 1.76m or 12.10% of revenues. In addition the company used 935.06k for operations while cash used for investing totalled 479.13k.
Cash flow per share0.0073
Price/Cash flow per share59.43
Book value per share0.0908
Tangible book value per share0.0763
More ▼

Balance sheet in USDView more

Aurora Spine Corp has a Debt to Total Capital ratio of 42.42%, a lower figure than the previous year's 90.27%.
Current ratio2.40
Quick ratio1.38
Total debt/total equity0.7368
Total debt/total capital0.4242
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.